Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

Specimen Handling 200Magnetic Resonance Spectroscopy 151Biopsy 113Nivolumab 40Immunoglobulin G 40Disulfides 40Cisplatin 38Cyclophosphamide 37Platinum 36Paclitaxel 361,2-diaminocyclohexaneplatinum II citrate 36Carboplatin 35Taxes 34Radiation 34X-Rays 29Radiotherapy 28pembrolizumab 27Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 22Gemcitabine 22Vincristine 19Prednisone 19fludarabine 18Ipilimumab 18CTLA-4 Antigen 18venetoclax 17durvalumab 17Phantoms, Imaging 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × gilteritinib × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06317649 2026-06-05

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
147 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡